Medizinische Klinik und Poliklinik I, University Clinic Carl Gustav Carus
Welcome,         Profile    Billing    Logout  
 13 Trials 
19 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Platzbecker, Uwe
TUD-APOLLO-064, NCT02688140 / 2015-001151-68: Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Active, not recruiting
3
280
Europe
Arsenic trioxide, ATO, Trisenox (R), As2O3, Idarubicin, IDA, Cytarabine, Ara-C, Tretinoin, all-trans retinoic acid, ATRA, Mitoxantrone, MTZ, Mercaptopurine, 6-Mercaptopurine, 6-MP, Methotrexate, MTX
Technische Universität Dresden, Gruppo Italiano Malattie EMatologiche dell'Adulto, Groupe Francophone des Myelodysplasies, HOVON - Dutch Haemato-Oncology Association, Programa para el Tratamiento de Hemopatías Malignas, German Federal Ministry of Education and Research, Teva Pharmaceuticals Europe
Acute Promyelocytic Leukemia
01/25
01/25
NCT04712942: Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat

Completed
2
14
Europe
Pevonedistat, Azacitidine
University of Leipzig, Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Minimal Residual Disease
01/23
01/23
PEMAZA, NCT03769532 / 2017-004110-25: MRD-guided Treatment in NPM1mut AML Patients

Recruiting
2
28
Europe
Pembrolizumab, PEM, Keytruda®, Azacitidine, AZA, Vidaza®
Technische Universität Dresden, Merck Sharp & Dohme LLC
Acute Myeloid Leukemia
08/23
08/24
IMpress, NCT05583552: Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy

Active, not recruiting
2
23
Europe, RoW
Imetelstat, GRN163L
GCP-Service International West GmbH, Geron Corporation, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, QIMR Berghofer Medical Research Institute, Australasian Leukaemia and Lymphoma Group, Groupe Francophone des Myelodysplasies, German Myelodysplastic Syndrome Study Group
Myelodysplastic Syndromes, Acute Myeloid Leukemia
02/25
06/26
LUCAS, NCT05178342: Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

Terminated
2
38
Europe
CA-4948, Emavusertib
University of Leipzig, Curis, Inc.
Myelodysplastic Syndromes, Anemia
03/24
03/24
REMARK_001, NCT06243458: RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Not yet recruiting
2
41
Europe
RVU120 (SEL120)
GCP-Service International West GmbH, Universitätsklinikum Leipzig, Saint-Louis Hospital, Paris, France, University of Florence, University of Salamanca, Medical University of Warsaw, Ryvu Therapeutics SA, European Myelodysplastic Neoplasms Cooperative Group
Low Risk Myelodysplastic Syndromes
05/26
05/27
PALOMA, NCT04061239 / 2018-002430-21: Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML

Recruiting
2
150
Europe
CPX-351, Vyxeos, Daunorubicin, Cytarabine, Azacitidine, Vidaza
GWT-TUD GmbH
MDS, AML
03/26
09/26
MAGROLIC, NCT05829434: Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

Withdrawn
2
108
NA
Magrolimab, Hu5F9-G4, GS-4721, 7+3, Daunorubicine and Cytarabine, CPX-351, Vyxeos®
Uwe Platzbecker, Gilead Sciences
Acute Myeloid Leukemia, Myelodysplastic Neoplasm
08/28
08/29
APTIVATE, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
218
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax
Aptose Biosciences Inc.
Relapsed or Refractory Acute Myeloid Leukemia
02/24
08/24
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
ImmunoGen, Inc., Jazz Pharmaceuticals
Acute Myeloid Leukemia
12/24
12/24
CA-4948-102, NCT04278768: Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With AML or MDS

Recruiting
1/2
366
Europe, US, RoW
Emavusertib, CA-4948, Venetoclax
Curis, Inc.
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
04/26
04/26
GEMINI II, NCT04718844: A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome

Completed
1
44
Europe, RoW
SLN124, Placebo
Silence Therapeutics plc
Non-transfusion-dependent Thalassemia, Low Risk Myelodysplastic Syndrome, Very-Low Risk Myelodysplastic Syndrome
05/23
05/23
NCT04174547: An European Platform for Translational Research in Myelodysplastic Syndromes

Recruiting
N/A
8670
Europe
Istituto Clinico Humanitas
Myelodysplastic Syndromes
09/21
09/22
GENOMED4ALL, NCT04889729: Improving MDS Classification and Prognosis by AI

Active, not recruiting
N/A
13284
Europe
Istituto Clinico Humanitas
Myelodysplastic Syndromes
12/22
12/24
NCT02192619: National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup

Recruiting
N/A
500
Europe
observational
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Newly-diagnosed APL (de Novo or Therapy-related), Relapsed APL
12/24
12/24
BoHemE, NCT02867085: Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly

Recruiting
N/A
356
Europe
Observational
Technische Universität Dresden
Myelodysplastic Syndromes
12/23
12/23
Naumann, Ralph
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
NCT05008809: Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)

Recruiting
3
507
Europe
mFOLFOX6, Leucovorin, Oxaliplatin, 5-fluorouracil (FU), mFOLFOXIRI, Leucovorin, Oxaliplatin, 5-FU, Irinotecan
Dominik Paul Modest, German Research Foundation, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer
11/27
11/30
NCT03188874: Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

Recruiting
N/A
15000
Europe
Technische Universität Dresden
Acute Myeloid Leukemia (AML)
09/30
09/30

Download Options